

Let's Beat DIABETES with Perfect Trio

Sitahenz-DM 500

Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin (Extended Release) 500 mg Tablets

Sitahenz-DM 1000

Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin (Extended Release) 1000 mg Tablets

Sitahenz-DM 500

Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin (Extended Release) 500 mg Tablets

Sitahenz-DM 1000

Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin (Extended Release) 1000 mg Tablets

BACKGROUND:

For patients with type 2 diabetes, multiple agents with complementary mechanisms of action are often required to adequately manage hyperglycemia. Many currently available combinations are associated with hypoglycemia and/or weight gain, effects that act as barriers to the achievement of glycemic and weight control. Therefore, an unmet need exists for new agents to treat Diabetes. The FDC of an SGLT-2 inhibitor, a DPP-4 inhibitor and Biguanide provide a new avenue for the management of Hyperglycemia. The combination of an SGLT-2 inhibitor, a DPP-4 inhibitor, has shown superior efficacy when added to metformin compared with add-on of either monotherapy alone.

DESCRIPTION:

Sitahenz-DM 500: is a film coated tablet contains Sitagliptin 100 mg, Dapagliflozin 10 mg and Metformin (Extended Release) 500 mg Tablets

Sitahenz-DM 1000: is a film coated tablet contains Sitagliptin 100 mg, Dapagliflozin 10 mg and Metformin (Extended Release) 1000 mg Tablets

INDICATION:

Sitahenz-DM 500/1000 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

MECHANISM OF ACTION:

- Sitagliptin selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide to facilitate glucose regulation in response to a meal.
- Dapagliflozin inhibits SGLT2 and blocks reabsorption of filtered glucose in the kidney, thereby increases urinary glucose excretion and reduces blood glucose levels. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.
- Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing
 the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.

DOSAGE:

Sitahenz-DM 500: One Tablet daily or as prescribed by the doctor. **Sitahenz-DM 1000:** One Tablet daily or as prescribed by the doctor.

References: Diabetes Obes Metab. 2020;22:1083–1093. Diabetes Care 2014;37(3):740–750

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998 E-mail: info@larenon.com | Web: www.larenon.com

